Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Defined term · Outcomes and endpoints

Discontinuation for adverse events

Cessation of randomised treatment because of an adverse event. Reported by the Institute in the summary-of-findings table alongside efficacy outcomes rather than in a tolerability annex.

Document identifier
CEI-GT-100
Series
Defined term
Version
1.0
Published
30 Jul 2026
Last reviewed
30 Jul 2026
Certainty
Not rated

§1Discontinuation for adverse events

§1.2Category

Outcomes and endpoints — Terms describing what a study measures and what the measurement supports.

§1.3Related terms

  • Adverse event — Any untoward occurrence in a participant, whether or not attributed to treatment. Ascertained by spontaneous report in most trials, which underestimates incidence…
  • Attrition — Loss of participants from a trial before its primary analysis timepoint. Differential attrition between arms threatens the comparability that randomisation established.
Compound Evidence Institute · CEI-GT-100 · https://compoundevidence.com/glossary/discontinuation-for-adverse-events/ · retrieved 30 July 2026
Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.